Vaccine developer Advaxis is teaming up with CRO inVentiv Health to advance a stable of oncology candidates that work by mounting an immune system attack on cancer tissue.
GlaxoSmithKline's oncology division is retooling and adding a new focus on the emerging field of T-cell engineering in immuno-oncology. And in the process the pharma giant is sending a clear message that it still sees a bright future for itself in cancer drug research.
Qiagen and Eli Lilly have joined forces for their fourth companion diagnostics project, building on the momentum of past collaborations to develop assay panels for cancer.
Qiagen and Eli Lilly have clicked well enough in previous companion diagnostics development projects that they're signing up for a fourth go-around.
As rates of drug-resistant tuberculosis rise across the globe, GlaxoSmithKline is partnering with Switzerland's BioVersys and France's University of Lille to develop a preclinical candidate against the airborne disease.
Array BioPharma has watched its shares fall steadily earthward since ex-partner Amgen backed out of a diabetes deal last summer, but a new deal with Big Biotech Biogen Idec sent the company up about 5% on renewed hopes for its early-stage R&D efforts.
The U.K.'s PolyTherics, which just this week merged with Antitope to pool their resources in R&D, announced that it would also collaborate with Canadian company Alpha Cancer Technologies, which has a drug delivery platform called alpha fetoprotein designed to enhance chemotherapy.
The Chinese government approved a joint venture between Italian cardiac device giant Sorin and MicroPort Scientific, paving the way for the new company to grab a share of the country's growing healthcare market.
Clinical trial software provider Clinverse has inked a deal with eClinical Insights to share resources and unite their technologies.
Following fast on the heels of two earlier immuno-oncology partnerships, Incyte has agreed to partner its prolific IDO inhibitor INCB24360 with Bristol-Myers Squibb's marquee PD-1 program for nivolumab. And with just days to go before the start of ASCO, Bristol-Myers also inked a biobucks-packed $1.24 billion deal with South San Francisco-based CytomX to broaden its pipeline of immuno-oncology drugs with up to four new clinical candidates spawned by its next-gen antibody development platform.